Prophylaxis in von Willebrand disease.

Area of Science:

• Hematology
• Pharmacology
• Internal Medicine

Background:

• Von Willebrand disease (VWD) management requires tailored strategies for patients unresponsive to desmopressin.
• Standard treatment involves factor concentrates containing von Willebrand factor (VWF) and factor VIII (FVIII), with dosing considerations for product variability.
• Peri-operative VWD management depends on disease subtype, baseline factor levels, and procedure complexity.

Purpose of the Study:

• To review current issues in short-term and long-term prophylaxis for desmopressin-unresponsive VWD patients.
• To evaluate the role of VWF-containing concentrates in VWD prophylaxis.
• To highlight the need for evidence-based guidelines for VWD prophylaxis.

Main Methods:

• Review of current literature and clinical data on VWD treatment strategies.
• Analysis of dosing considerations for VWF and FVIII concentrates.
• Examination of outcomes from prophylaxis studies in VWD patients.

Main Results:

• Long-term prophylaxis with VWF-containing concentrates is not standard but shows potential benefits in VWD.
• A study of 35 Swedish VWD patients demonstrated significant reductions in bleeding episodes with prophylaxis.
• Early prophylaxis in children (before age 5) showed no signs of arthropathy.

Conclusions:

• VWF-containing concentrates may offer significant benefits for VWD prophylaxis, particularly for bleeding symptoms.
• Further research and evidence-based guidelines are crucial for establishing VWD prophylaxis protocols.
• Prophylaxis is a promising therapeutic avenue for select VWD patients.